Metformin versus pioglitazone in treatment of polycystic ovarian syndrome - A randomized control trial
Medicine and Clinical Science · 2020
DOI: 10.33425/2690-5191.1016 ↗Kurz gefasst
Fachartikel in der Zeitschrift Medicine and Clinical Science, 2020. Verfasst von Jahanara Ainuddin und 4 weiteren Autor:innen.
Abstract (Originalsprache)
Objective
To compare the efficacy of metformin versus pioglitazone in the treatment of polycystic ovarian syndrome.
Methods
A prospective randomized controlled trial with parallel assignment was conducted in the outpatient Gynecology clinic of Dow University Hospital and Mamji Hospital, Karachi, Pakistan.One hundred and twenty patients with polycystic ovarian syndrome were selected and randomized into two groups with 60 patients receiving metformin in dose of 500mg TDS and 60 receiving pioglitazone 30mg daily.Clinical and biochemical parameters were evaluated at recruitment and at six months after treatment.Data was entered and analyzed through SPSS version 21.
Results
Patients in both groups were Age and BMI matched.Significant reductions in fasting insulin levels, total testosterone and free androgen levels were found in both groups after treatment (p
Zitieren
APA
Ainuddin, J., Islam, M., Rabia, S., Farooqui, W. A., & Islam, A. (2020). Metformin versus pioglitazone in treatment of polycystic ovarian syndrome - A randomized control trial. Medicine and Clinical Science. https://doi.org/10.33425/2690-5191.1016
Vancouver
Ainuddin J, Islam M, Rabia S, Farooqui WA, Islam A. Metformin versus pioglitazone in treatment of polycystic ovarian syndrome - A randomized control trial. Medicine and Clinical Science. 2020. doi:10.33425/2690-5191.1016
BibTeX
@article{Ainuddin2020,
author = {Ainuddin, Jahanara and Islam, Musfera and Rabia, Syeda and Farooqui, Waqas Ahmed and Islam, Ashi},
title = {Metformin versus pioglitazone in treatment of polycystic ovarian syndrome - A randomized control trial},
journal = {Medicine and Clinical Science},
year = {2020},
doi = {10.33425/2690-5191.1016}
}
EUVIMED